Loading company
Zhengye Biotechnology Holding Limited
ZYBT · Nasdaq · ·
$1.500.0%Nov 13 close
Figures through June 30, 2026, from the 6-K filed November 12, 2026
Past performance
- 1W
- 0.0%
- 1M
- 0.0%
Zhengye Biotechnology Holding Limited against drug manufacturers specialty and generic
Zhengye Biotechnology Holding Limited is the 59th largest of 78 graded companies. Showing 5 of them, including ZYBT itself. 6 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Inmed Pharmaceuticals Inc.INM | F- | — | $4.5M | -292.1% | -$8.1M | — |
| Indivior Pharmaceuticals, Inc.INDV | A | — | $1.4B | 32.8% | $31M | — |
| Teva Pharmaceutical Industries LimitedTEVA | C | $51.9B | $17.2B | 2.9% | $1.2B | 103.49 |
| Haleon plcHLN | B+ | $41B | $14.8B | 15.1% | $3.1B | 18.50 |
| Zhengye Biotechnology Holding LimitedZYBT | D | $71.1M | $15.7M | -63.9% | $1.8M | — |
73 more drug manufacturers specialty and generic companies
Graded on the same five checks, from their own SEC filings.
How it compares with its industry
Three ratings, each a percentile against the 81 companies we cover in Drug Manufacturers Specialty and Generic. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.
Momentum
30of 100 in its industry
Below most of its industry
12 months to a month ago-48.3%
6 months to a month ago23.3%
The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.
Value
44of 100 in its industry
Middle of its industry
Profit for the price-14.13%
Cash for the price2.60%
Sales for the price22.13%
Assets for the price52.68%
Operating profit for the whole business—
Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 4 of 5 measures.
Capital allocation
1/4Loose
2 checks not reported
Return on capital-17.1%
Shareholder yield3.38%
Share count, 3 years3.8%
Net debt / EBITDA—
Insiders, 12 months—
What management does with the money — scored on whatever the filings answer, never as a share of the total.
The six capital-allocation checks
- Return on the money invested-17.1% on invested capital
- Debt against earningsNo comparable earnings to measure debt against
- Cash returned to shareholders3.4% a year in buybacks and dividends
- Share count over three yearsShare count 3.8% higher over three years
- Payouts covered by cash flowPays out more than it generates
- Open-market insider buyingNo open-market insider dealing on file
A description of where this company sits among its competitors, not a recommendation. Ratings updated Nov 15, 2026.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Zhengye Biotechnology Holding Limited on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.